AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31926605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous siponimod (1 mg/24 h)
Number of subjects: 33
Study 31926605 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral siponimod (0.25 mg)
Number of subjects: 33
Study 31926605 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous siponimod (0.25 mg/3 h) and Oral siponimod (0.25 mg)
Number of subjects: 33
Study 29480043 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment
Number of subjects: 153
Study 29480043 — intervention group
Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 153
Study 29480043 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 153
Study 28450218 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider-delivered patient financial incentive ($50 for completing online ACP tool and a lottery for discussing ACP)
Number of subjects: 367
Study 28450218 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail-delivered patient financial incentive
Number of subjects: 367
Study 25475516 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghost ileostomy (GI)
Number of subjects: 55
Study 25475516 — intervention group
Group type: COMPARATOR
Intervention: No protective stoma (Control group B)
Number of subjects: 55
Study 23279198 — intervention group
Group type: EXPERIMENTAL
Intervention: 5Hz rTMS over contra-lesional pharyngeal motor cortex for 10 min per day for 2 weeks
Number of subjects: 18
Study 23279198 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation under the same condition
Number of subjects: 18
Study 21649852 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-day brief intervention smoking cessation training
Number of subjects: 57
Study 18088400 — intervention group
Group type: EXPERIMENTAL
Intervention: MegaCHOP for three courses followed by BEAM and ASCT
Number of subjects: 86
Study 18088400 — intervention group
Group type: EXPERIMENTAL
Intervention: IFE followed by BEAM and ASCT
Number of subjects: 86
Study 18088400 — intervention group
Group type: COMPARATOR
Intervention: MegaCHOP and BEAM/ASCT
Number of subjects: 86
Study 16931680 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypercapnia (end‐tidal Pco2 50 mm Hg)
Number of subjects: 30
Study 16931680 — intervention group
Group type: COMPARATOR
Intervention: Normocapnia (end‐tidal Pco2 35 mm Hg)
Number of subjects: 30
Study 12544376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.25 mg
Number of subjects: 47
Study 12544376 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1 mg
Number of subjects: 47
Study 12544376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 11130251 — intervention group
Group type: EXPERIMENTAL
Intervention: IV granisetron (G) 3 mg once a day
Number of subjects: 45
Study 11130251 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tropisetron (T) 5 mg once a day
Number of subjects: 45
Study 11130251 — intervention group
Group type: COMPARATOR
Intervention: IV ondansetron (O) 8 mg twice daily
Number of subjects: 45
Study 11130251 — intervention group
Group type: EXPERIMENTAL
Intervention: IV granisetron (G)
Number of subjects: 45
Study 11130251 — intervention group
Group type: EXPERIMENTAL
Intervention: IV tropisetron (T)
Number of subjects: 45
Study 11130251 — intervention group
Group type: COMPARATOR
Intervention: IV ondansetron (O)
Number of subjects: 45
Study 8847874 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate (200 mg/day)
Number of subjects: 133
Study 8847874 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (20 mg/day)
Number of subjects: 133
Study 8227493 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine treatment in OCD patients with chronic tic disorder
Number of subjects: 66
Study 8227493 — intervention group
Group type: COMPARATOR
Intervention: Fluvoxamine treatment in OCD patients without chronic tic disorder
Number of subjects: 66
Study 2941372 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic peptide 0.5 micrograms/min
Number of subjects: 8
Study 2941372 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic atrial natriuretic peptide 5.0 micrograms/min
Number of subjects: 8
Study 30280640 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral-valve repair plus medical therapy (device group)
Number of subjects: 614
Study 30280640 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone (control group)
Number of subjects: 614
Study 25643617 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity strength training with vascular occlusion (LI-BFR)
Number of subjects: 0
Study 25643617 — intervention group
Group type: COMPARATOR
Intervention: High-intensity strength training (HI)
Number of subjects: 0
Study 24729507 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 1 g
Number of subjects: 2060
Study 24729507 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg twice daily for 7 days
Number of subjects: 2060
Study 22107338 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic causes (for heart disease risk)
Number of subjects: 647
Study 22107338 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic causes (for depression)
Number of subjects: 647
Study 22107338 — intervention group
Group type: COMPARATOR
Intervention: Environmental, family history, family history & genetic test (for heart disease risk)
Number of subjects: 647
Study 22107338 — intervention group
Group type: COMPARATOR
Intervention: Severity (higher or low)
Number of subjects: 647
Study 19584736 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine
Number of subjects: 30
Study 19584736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18167160 — intervention group
Group type: EXPERIMENTAL
Intervention: extensively hydrolyzed formula (eHF)
Number of subjects: 77
Study 18167160 — intervention group
Group type: COMPARATOR
Intervention: amino acid formula (AAF)
Number of subjects: 77
Study 15633707 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotic-aiming task using selective dichotic-listening procedure
Number of subjects: 52
Study 12449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow waves and sharp waves (spikes)
Number of subjects: 255
Study 12449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Seizure-free patients
Number of subjects: 255
Study 12449847 — intervention group
Group type: EXPERIMENTAL
Intervention: EEG groups with slow and sharp waves
Number of subjects: 255
Study 12449847 — intervention group
Group type: EXPERIMENTAL
Intervention: First EEG record findings
Number of subjects: 255
Study 12449847 — intervention group
Group type: EXPERIMENTAL
Intervention: More slow waves and sharp waves
Number of subjects: 255
Study 12449847 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal slowing and rare discharges
Number of subjects: 255
Study 10351967 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation/scatter corrected images
Number of subjects: 184
Study 10351967 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation/scatter corrected data with quantitative analysis
Number of subjects: 184
Study 10351967 — intervention group
Group type: COMPARATOR
Intervention: Uncorrected perfusion data
Number of subjects: 184
Study 10351967 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation/scatter correction
Number of subjects: 184
Study 10351967 — intervention group
Group type: EXPERIMENTAL
Intervention: Attenuation/scatter correction methodology
Number of subjects: 184
Study 7580297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg)
Number of subjects: 7
Study 7580297 — intervention group
Group type: COMPARATOR
Intervention: LPS (20 micrograms)
Number of subjects: 7
Study 7580297 — intervention group
Group type: COMPARATOR
Intervention: Solvent solution
Number of subjects: 7
Study 1935285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held nebulizer (HHN) with metaproterenol
Number of subjects: 17
Study 1935285 — intervention group
Group type: COMPARATOR
Intervention: Metered dose inhaler (MDI) via spacer (InspirEase)
Number of subjects: 17
Study 1935285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held nebulizer (HHN) with metaproterenol in asthmatic patients
Number of subjects: 17
Study 1935285 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held nebulizer (HHN) with metaproterenol in COPD patients
Number of subjects: 17
Study 7025874 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine 50 mg
Number of subjects: 0
Study 7025874 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 100 microgram
Number of subjects: 0
Study 7025874 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 2 mg
Number of subjects: 0
Study 30852363 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 119
Study 30852363 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 119
Study 28494906 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine group (GB): 20ml 0.5% bupivacaine diluted in 20ml saline
Number of subjects: 60
Study 28494906 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine group (GM): 20ml 0.5% bupivacaine + 10mg morphine sulphate diluted in 20ml saline
Number of subjects: 60
Study 28494906 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine group (GM)
Number of subjects: 60
Study 28494906 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine group (GB)
Number of subjects: 60
Study 26920896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zedoary herbal tea (ZHT) T1 (500 mg ZRDP)
Number of subjects: 30
Study 26920896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zedoary herbal tea (ZHT) T2 (1 g ZRDP)
Number of subjects: 30
Study 26920896 — intervention group
Group type: EXPERIMENTAL
Intervention: Zedoary herbal tea (ZHT) T3 (1.5 g ZRDP)
Number of subjects: 30
Study 24336837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise (25 sessions over 13 weeks)
Number of subjects: 0
Study 24336837 — intervention group
Group type: COMPARATOR
Intervention: Regular soccer training (Control group)
Number of subjects: 0
Study 24336837 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic hamstring exercise
Number of subjects: 0
Study 21698213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 308
Study 21698213 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 20 mg
Number of subjects: 308
Study 21698213 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 308
Study 21698213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study 19554666 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced whole-heart MRA at 3.0 T using gadofosveset
Number of subjects: 20
Study 19554666 — intervention group
Group type: COMPARATOR
Intervention: Noncontrast-enhanced SSFP coronary MRA at 1.5 T
Number of subjects: 20
Study 17605568 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom promotion videotape (male presenter)
Number of subjects: 220
Study 17605568 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom promotion videotape (female presenter)
Number of subjects: 220
Study 17605568 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 220
Study 15322643 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% NaOCl
Number of subjects: 20
Study 15322643 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 20
Study 15322643 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 20
Study 15322643 — intervention group
Group type: COMPARATOR
Intervention: Distilled and deionized water
Number of subjects: 20
Study 11680070 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 4
Study 9012720 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammography arm
Number of subjects: 3
Study 9012720 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm
Number of subjects: 3
Study 7699642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1.5 g/kg every 2 weeks for 2 months, then monthly for 4 months (total: up to 9 infusions over 6 months)
Number of subjects: 31
Study 7699642 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.1% albumin)
Number of subjects: 31
Study 7699642 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG)
Number of subjects: 31
Study 7699642 — intervention group
Group type: COMPARATOR
Intervention: Intravenous immunoglobulin (IVIG) and Placebo
Number of subjects: 31
Study 3322590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (10 mg/m2) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Number of subjects: 60
Study 3322590 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (50-60 mg) with cyclophosphamide (500 mg/m2) and 5-fluorouracil (500 mg/m2)
Number of subjects: 60
Study 3322590 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (CNF)
Number of subjects: 60
Study 3322590 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (CAF)
Number of subjects: 60
Study 30069614 — intervention group
Group type: EXPERIMENTAL
Intervention: Online HIV prevention program (Keep It Up! 2.0)
Number of subjects: 2984
Study 30069614 — intervention group
Group type: COMPARATOR
Intervention: Recruitment from various venues (community-based organizations, Facebook, dating apps, outreach events)
Number of subjects: 2984
Study 27555133 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 1g paracetamol (Group P)
Number of subjects: 60
Study 27555133 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl solution (Group C)
Number of subjects: 60
Study 24519421 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% indomethacin eye drops, four times per day, 16 subjects = 23 eyes
Number of subjects: 31
Study 24519421 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle of INDOM), 15 subjects = 23 eyes
Number of subjects: 31
Study 22413021 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days a week postoperative radiotherapy (p-CAIR)
Number of subjects: 279
Study 22413021 — intervention group
Group type: COMPARATOR
Intervention: 5 days a week postoperative radiotherapy (CF)
Number of subjects: 279
Study 22413021 — intervention group
Group type: EXPERIMENTAL
Intervention: High PTEN expression
Number of subjects: 279
Study 22413021 — intervention group
Group type: EXPERIMENTAL
Intervention: PTEN expression as a predictor
Number of subjects: 279
Study 20667936 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine supplementation for 2 weeks
Number of subjects: 9
Study 20667936 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 9
Study 18980783 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA)
Number of subjects: 57
Study 18980783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 15743151 — intervention group
Group type: EXPERIMENTAL
Intervention: IP (irinotecan [Camptosar]/cisplatin [Platinòl])
Number of subjects: 0
Study 15743151 — intervention group
Group type: COMPARATOR
Intervention: EP (etoposide/cisplatin)
Number of subjects: 0
Study 12611908 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg/day ursodeoxycholic acid (UDCA) for 20 days
Number of subjects: 12
Study 12611908 — intervention group
Group type: COMPARATOR
Intervention: No bile acid supplement (control)
Number of subjects: 12
Study 10575906 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 0
Study 10575906 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E combined with potent inhibitors of platelet aggregation
Number of subjects: 0
Study 8932266 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 55
Study 8932266 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 55
Study 8932266 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus and Cyclosporine
Number of subjects: 55
Study 1914767 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg nifedipine
Number of subjects: 12
Study 1914767 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine
Number of subjects: 12
Study 1914767 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6408995 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful (FT) alone
Number of subjects: 95
Study 6408995 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful (FT) plus cyclophosphamide (Ex)
Number of subjects: 95
Study 6408995 — intervention group
Group type: EXPERIMENTAL
Intervention: Futraful (FT) plus Carboquone (CQ)
Number of subjects: 95
Study 6408995 — intervention group
Group type: COMPARATOR
Intervention: Overall response rate among the three groups
Number of subjects: 95
Study 30939189 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin premix with 5% RSM
Number of subjects: 674
Study 30939189 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin premix with 10% RSM
Number of subjects: 674
Study 30939189 — intervention group
Group type: EXPERIMENTAL
Intervention: High vitamin premix
Number of subjects: 674
Study 30939189 — intervention group
Group type: COMPARATOR
Intervention: Low vitamin premix
Number of subjects: 674
Study 28221061 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD Coach (n = 62)
Number of subjects: 120
Study 28221061 — intervention group
Group type: COMPARATOR
Intervention: Waitlist condition (n = 58)
Number of subjects: 120
Study 26644535 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 233
Study 26644535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 233
Study 25147806 — intervention group
Group type: EXPERIMENTAL
Intervention: Renadyl
Number of subjects: 22
Study 25147806 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 22
Study 23018640 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study 23018640 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone
Number of subjects: 0
Study 19713798 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief alcohol intervention
Number of subjects: 0
Study 19713798 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 17953679 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mug rhEGF
Number of subjects: 41
Study 17953679 — intervention group
Group type: COMPARATOR
Intervention: 25 mug rhEGF
Number of subjects: 41
Study 17953679 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 41
Study 15007527 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreas head resection (Beger technique)
Number of subjects: 0
Study 15007527 — intervention group
Group type: EXPERIMENTAL
Intervention: Variations of the Beger technique (Frey, Izbicky, Berne modification)
Number of subjects: 0
Study 11144988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (75 mg once daily)
Number of subjects: 10
Study 11144988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 11144988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib + digoxin
Number of subjects: 10
Study 11144988 — intervention group
Group type: COMPARATOR
Intervention: Placebo + digoxin
Number of subjects: 10
Study 11144988 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 10
Study 7928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise (30 and 90 watts on a cycle ergometer)
Number of subjects: 0
Study 7928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded exercise with CO2 addition
Number of subjects: 0
Study 7928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed external work load (10 minutes at 90 watts)
Number of subjects: 0
Study 7928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective beta 1‐adrenoceptor blockade (betaxolol) during graded exercise
Number of subjects: 0
Study 7928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonselective beta‐adrenoceptor blockade (levobunolol) during graded exercise
Number of subjects: 0
Study 7928182 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise with beta‐adrenoceptor blockade
Number of subjects: 0
Study 2654206 — intervention group
Group type: EXPERIMENTAL
Intervention: MEFAE sodium 720 mg daily
Number of subjects: 36
Study 2654206 — intervention group
Group type: EXPERIMENTAL
Intervention: DMFAE 240 mg daily
Number of subjects: 36
Study 2654206 — intervention group
Group type: COMPARATOR
Intervention: MEFAE sodium up to 240 mg daily
Number of subjects: 36
Study 968056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Tylose)
Number of subjects: 60
Study 968056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium (Hyskon)
Number of subjects: 60
Study 968056 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg 15(S)‐15 methyl PGF2alpha in non‐viscous medium repeated at 12 hours
Number of subjects: 60
Study 968056 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg 15(S)‐15 methyl PGF2alpha in viscous medium
Number of subjects: 60
Study 31981370 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusion Tensor Imaging (DTI) parameters including fractional anisotropy, mean diffusivity (MD), axial diffusivity (AxD), and radial diffusivity (RD)
Number of subjects: 227
Study 29058097 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (cisplatin 80 mg/m2 for six cycles plus capecitabine 1000 mg/m2 orally bid days 1-14 or 5-fluorouracil 800 mg/m2/day continuous IV infusion days 1-5 every 3 weeks)
Number of subjects: 387
Study 28352842 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping mesh
Number of subjects: 30
Study 28352842 — intervention group
Group type: COMPARATOR
Intervention: Polypropylene mesh with fibrin glue fixation
Number of subjects: 30
Study 24598306 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (two intravenous doses of 250 mg each)
Number of subjects: 7000
Study 24598306 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7000
Study 24598306 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 7000
Study 24598306 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone and placebo
Number of subjects: 7000
Study 22524991 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful Awareness in Body-oriented Therapy (MABT)
Number of subjects: 31